ImmunityBio, Inc. (IBRX)
| Market Cap | 3.55B |
| Revenue (ttm) | 622,000 |
| Net Income (ttm) | -583.20M |
| Shares Out | 673.95M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,554,972 |
| Open | 4.91 |
| Previous Close | 4.91 |
| Day's Range | 4.82 - 5.31 |
| 52-Week Range | 1.25 - 6.93 |
| Beta | 0.04 |
| Analysts | Hold |
| Price Target | 5.00 (-5.12%) |
| Earnings Date | May 9, 2024 |
About IBRX
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus... [Read more]
Financial Performance
In 2023, ImmunityBio's revenue was $622,000, an increase of 159.17% compared to the previous year's $240,000. Losses were -$583.20 million, 40.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for IBRX stock is "Hold" and the 12-month stock price forecast is $5.0.
News
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the recent publication of preclinical data in the online issue of Science, Fir...
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cell...
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that enrollment and initial follow-up has been completed for the safety portio...
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that findings from Patient-Reported Outcomes (PROs) of participants in t...
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing...
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 35th Annual Piper Sandler ...
First Data for ImmunityBio's Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced new data showing that the company's Memory Cytokine-Enriched Natural Kil...
FDA Accepts ImmunityBio's BLA Resubmission as Complete and Sets New PDUFA Date
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has completed the resubmission of its Biologics License Application (...
ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing transactions resulting in approximately $...
IBRX DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action – IBRX
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and May 10, 2023, both date...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ImmunityBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 29, 2023 - (NASDAQ: IBRX)
NEW YORK , Aug. 29, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc.. Shareholders who purchased shares of IBRX during the class period listed a...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ImmunityBio, Inc. (IBRX)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 29, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investo...
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 29, 2023 in the Class Action Filed on Behalf of ImmunityBio, Inc. (IBRX) Shareholders
NEW YORK , Aug. 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) alleging that the Compa...
AUGUST 29 FINAL DEADLINE: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc.(IBRX) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Aug. 24, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) of a class action securities lawsuit. CLASS DEFIN...
IBRX FINAL DEADLINE TUESDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX
NEW YORK , Aug. 23, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and May 10, 2...
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $750,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio...
IMPORTANT AUGUST DEADLINE: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio...
FINAL DEADLINE THIS MONTH: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio...
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , Aug. 18, 2023 /PRNewswire/ -- Law Offices of Howard G.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ImmunityBio, Inc. of Class Action Lawsuit and Upcoming Deadline - IBRX
NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX), and certain offic...
IBRX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving ImmunityBio, Inc.
NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased ImmunityBio, Inc. ("Immunit...